Investors are thrilled with a new addition to BioCryst's board of directors.
News & Analysis: BioCryst Pharmaceuticals
BCRX earnings call for the period ending June 30, 2019.
A hedge fund disclosed a sizable stake in the company.
Tough conditions for these companies left them out of the day's rally.
This is a case study of when a successful phase 3 trial isn't successful enough.
BCRX earnings call for the period ending March 31, 2019.
BCRX earnings call for the period ending December 31, 2018.
Believe it or not, share prices rose after the company announced a share offering.
Investors are cheering the orphan drug specialist's decision to raise a nice chunk of capital via a public offering.
Shares plunge after its proposed merger is called off. Here's what investors need to know.